Gepotidacin
Gepotidacin (BLUJEPA) is a novel triazaacenaphthylene antibacterial medication classified under ATC-J01. It works by selectively inhibiting bacterial topoisomerase II enzymes (DNA gyrase and topoisomerase IV), disrupting bacterial DNA replication. This antibiotic is designed to treat urinary tract infections (UTIs) in patients who have limited or no alternative treatment options, particularly those caused by bacteria resistant to standard therapies.
Gepotidacin is a new antibacterial medication for treating urinary tract infections by inhibiting bacterial DNA replication through a novel mechanism targeting topoisomerase II enzymes.
Key facts at a glance
- ATC
- J01XX13
- RxNorm
- 2709212
- Generic
- Gepotidacin
- Class
- atc-j01
- Brands
- Blujepa
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Gepotidacin is indicated for the treatment of uncomplicated urinary tract infections (UTIs) in adult females who have limited or no alternative treatment options. It targets bacterial pathogens commonly associated with UTIs, including those resistant to other antibiotic classes.
Gepotidacin is a novel triazaacenaphthylene antibiotic that selectively inhibits bacterial topoisomerase II enzymes, specifically DNA gyrase and topoisomerase IV. By inhibiting these essential bacterial enzymes, it prevents DNA replication and transcription, ultimately leading to bacterial cell death.
As a new antibacterial agent, gepotidacin is designed to address rising antibiotic resistance. It should be used only when clinically appropriate and according to local prescribing guidelines. Common adverse reactions may include gastrointestinal symptoms. Healthcare providers should confirm bacterial susceptibility before initiating therapy. Clinical monitoring for treatment response is recommended.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy